Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Viking Therapeutics (VKTX) priced concurrent stock and convertible-note offerings totaling $500 million on September 24, 2026. The stock offering covers 7,857,143 shares at $35.00 each; the note offering comprises $225.0 million of 2.00% senior unsecured notes due October 15, 2032. Each offering was upsized from $200.0 million. Settlement is scheduled for September 25, subject to customary closing conditions. Neither offering depends on the other closing.
Viking estimates net proceeds of approximately $258.2 million from the shares and approximately $218.0 million from the notes, before any underwriter options are exercised. The notes initially convert at 19.7044 shares per $1,000 of principal, equivalent to approximately $50.75 per share—a premium of approximately 45% to the stock offering price. Viking intends to use the proceeds for its VK2735 and VK3019 programs, other research and development, working capital and general corporate purposes.
Viking Therapeutics (VKTX) proposed separate stock and convertible-note offerings of $200.0 million each on September 23, 2026.
Both offerings are subject to market and other conditions, and neither depends on the other closing. Viking expects to grant separate 30-day underwriter options for up to an additional $30.0 million of stock and $30.0 million in notes. The senior unsecured notes mature on October 15, 2032, unless repurchased, redeemed or converted earlier. Their interest rate and initial conversion rate will be set at pricing.
Viking intends to use the net proceeds for VK2735 development and commercialization, VK3019 development, and other research and development, working capital and general corporate purposes.
Viking Therapeutics (VKTX) reported positive topline results from a 33-week study of GLP-1/GIP agonist VK2735 in obesity, including a 22% placebo-adjusted mean weight loss at Week 33 for the 17.5 mg once-weekly cohort, with no plateau observed.
Across 21 weeks of induction, VK2735 produced mean weight loss of approximately 16–19% versus ~0% for placebo, with 65% of treated participants achieving at least 15% weight loss and 32% achieving at least 20%. In the 12-week maintenance phase, every-other-week dosing preserved up to 97% of prior weight loss and monthly dosing up to 90%, compared with 61% for placebo, with statistically significant separation from placebo. An exploratory arm continuing 17.5 mg weekly reached 21.7% mean weight loss at Week 33. Gastrointestinal adverse event rates and discontinuations during maintenance were low and generally similar to placebo. The company plans an oral maintenance part 2 study.
Viking Therapeutics (VKTX) will participate in three September 2026 healthcare investor events: the Cantor Global Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum, all held in New York, NY.
Viking management will join fireside chats and investor meetings at each conference. The Cantor fireside chat is scheduled for September 11, the Morgan Stanley session for September 14 with a live webcast and replay via Viking’s website, and the Bernstein session for September 23.
Viking Therapeutics (Nasdaq: VKTX) reported second quarter 2026 results and a corporate update, highlighting full enrollment of its Phase 3 VANQUISH-1 and VANQUISH-2 trials of subcutaneous VK2735 in obesity and obesity with type 2 diabetes. Both 78-week, randomized, placebo-controlled studies continued to progress as planned.
Viking is preparing to initiate Phase 3 trials of oral VK2735 for obesity in 4Q26 and expects data from a Phase 1 VK2735 maintenance dosing study in 3Q26. A Phase 1 single ascending dose trial of amylin agonist VK3019 has begun. The company ended the quarter with $502 million in cash. For Q2 2026, research and development expenses rose to $115.8 million, general and administrative expenses to $16.9 million, and net loss to $128.0 million, or $1.10 per share.
Viking Therapeutics (NASDAQ: VKTX) appointed Dorothy Gemmell to its Board of Directors, effective immediately. Gemmell brings more than 25 years of leadership experience across healthcare, digital health and commercialization, including prior roles as president or chief commercial officer at GoodRx, Capsule and Havas Life.
According to Viking, she has led growth initiatives, scaled organizations and developed revenue models across payer, provider, employer and pharmaceutical markets, and advises venture- and private equity-backed companies on commercialization strategies. Management highlights her appointment as the company advances its metabolic pipeline and prepares for VK2735’s potential launch, aiming to strengthen commercialization capabilities.
Viking Therapeutics (NASDAQ: VKTX) will release its second quarter 2026 financial results after the market close on Wednesday, July 29, 2026. The company will host a conference call the same day at 4:30 p.m. Eastern Time to review the results and provide corporate updates.
Investors can join by phone using U.S. and international dial-in numbers or listen via a live webcast on Viking’s investor relations website. A telephone replay will be available until August 5, 2026, and a webcast archive will remain online for 30 days.
Viking Therapeutics (NASDAQ:VKTX) has begun a Phase 1 single ascending dose study of VK3019, a dual amylin and calcitonin receptor agonist, in healthy adults with BMI ≥30. The randomized, double-blind, placebo-controlled trial assesses safety, tolerability, pharmacokinetics, and exploratory effects on body weight.
VK3019 expands Viking’s obesity pipeline, which includes Phase 3 VANQUISH trials of injectable dual GLP-1/GIP agonist VK2735, planned Phase 3 work on oral VK2735, and advanced programs VK2809 for NASH and VK0214 for X-ALD.
Viking Therapeutics (NASDAQ: VKTX) appointed Hubert C. Chen, M.D. as chief medical officer, reporting to CEO Brian Lian. He will oversee clinical development, medical, and regulatory affairs as Viking advances late-stage programs, including potential commercialization of obesity candidate VK2735.
Dr. Chen brings more than two decades of biotech leadership across drug discovery, clinical development, regulatory strategy, and product approvals in metabolic and endocrine disorders, including prior C-level roles at Loyal Animal Health, Forte Biosciences, Metacrine, and Pfenex.
Viking Therapeutics (NASDAQ:VKTX) will present at two June 2026 investor conferences: the William Blair 46th Annual Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York.
Management will host a corporate presentation, breakout session, fireside chat, and investor meetings, with a live webcast and replay for the Jefferies fireside chat.